|
Medical News |
|
Ganfyd - Recent changes [en]
|
Track the most recent changes to the wiki in this feed.
|
-
RYR2
subclude
New page {{GeneticsBox}}
{{:Ryanodine receptor 2}}
[[Category:Genes]]
-
Ryanodine receptor 1
categorise
| ?Older revision |
Revision as of 23:23, 7 February 2012 |
| Line 3: |
Line 3: |
| | [[Category:Membrane proteins]] | | [[Category:Membrane proteins]] |
| | [[Category:Ryanodine receptors]] | | [[Category:Ryanodine receptors]] |
| | + | [[Category: Receptor proteins]] |
| | </noinclude> | | </noinclude> |
| - | The [[ryanodine receptor 1]], a calcium release channel, is a very large peptide at 5038 amino acids coded by the gene [[RYR1]]. Mutations cause: | + | The [[ryanodine receptor 1]], a calcium release channel, is a very large peptide at 5038 amino acids coded by the gene [[RYR1]] at 19q13.1. Mutations cause: |
| | * [[Malignant hyperpyrexia]] | | * [[Malignant hyperpyrexia]] |
| | * [[Central core disease]] of muscle | | * [[Central core disease]] of muscle |
| | * [[Multiminicore disease with external ophthalmoplegia]] (MMDO) | | * [[Multiminicore disease with external ophthalmoplegia]] (MMDO) |
| | * [[Congenital myopathy with fiber-type disproportion]] (CFTD) | | * [[Congenital myopathy with fiber-type disproportion]] (CFTD) |
-
Ryanodine receptor 2
wanted
New page <noinclude>
{{biochemistryBox|||Cardiac muscle ryanodine receptor-calcium release channel, cardiac muscle-type ryanodine receptor, RYR-2, RyR2, hRYR-2}}
[[Category:Membrane proteins]]
[[Category:Ryanodine receptors]]
[[Category: Receptor proteins]]
</noinclude>
The [[ryanodine receptor 2]] is a 4967 amino acid peptide coded by the gene [[RYR2]] at 1q42.1-q43. Mutations cause:
* [[Familial arrhythmogenic right ventricular dysplasia type 2]] (ARVD2, arrhythmogenic right ventricular cardiomyopathy 2, ARVC2).
* [[Catecholaminergic polymorphic ventricular tachycardia type 1]] (CPVT1, stress-induced polymorphic ventricular tachycardia, VTSIP)
-
Category:Ryanodine receptors
important family of proteins
New page {{SubjectBox}}
[[Category:Receptor proteins]]
The ryanodine receptor family of homotetramer multi-pass membrane proteins that have calcium release channel activity.
-
RYR1
sub
New page {{GeneticsBox|||RYDR}}
{{:Ryanodine receptor 1}}
[[Category:Genes]]
-
Malignant hyperthermia
redirect
New page #redirect[[Malignant hyperpyrexia]]
[[Category:Anaesthetics]]
[[Category:Psychiatry]]
[[Category:Neurology]]
-
Ryanodine receptor 1
malignant hyperthermia
New page <noinclude>
{{biochemistryBox|||Skeletal muscle calcium release channel, skeletal muscle-type ryanodine receptor, RYR-1, RyR1}}
[[Category:Membrane proteins]]
[[Category:Ryanodine receptors]]
</noinclude>
The [[ryanodine receptor 1]], a calcium release channel, is a very large peptide at 5038 amino acids coded by the gene [[RYR1]]. Mutations cause:
* [[Malignant hyperpyrexia]]
* [[Central core disease]] of muscle
* [[Multiminicore disease with external ophthalmoplegia]] (MMDO)
* [[Congenital myopathy with fiber-type disproportion]] (CFTD)
-
Malaria
| ?Older revision |
Revision as of 15:16, 6 February 2012 |
| Line 7: |
Line 7: |
| | [[insect vectors|Anopheles]] mosquitoes capable of carrying the disease exist in England, but the climate is currently too cool at some times of year for the malarial parasite to complete its lifecycle. As global warming bites, it may return to temperate areas such as Exeter, England, where in Roman times it was present. | | [[insect vectors|Anopheles]] mosquitoes capable of carrying the disease exist in England, but the climate is currently too cool at some times of year for the malarial parasite to complete its lifecycle. As global warming bites, it may return to temperate areas such as Exeter, England, where in Roman times it was present. |
| | | | |
| - | Malaria has been with human beings for a long time in evolutionary terms, as seen in the numerous genetic mutations that occur for the express benefit of conferring partial immunity eg [[sickle cell trait]], [[G6PD]], [[hereditary spherocytosis]]. At the same time, the parasite has evolved multiple ways of avoiding the immune system, which is why developing a vaccine has proved so difficult. It is likely that our immune system has also evolved in response to pressure from the organism eg HLA B53 confers 40% protection vs severe malaria. | + | Malaria has been with human beings for a long time in evolutionary terms, as seen in the numerous genetic mutations that occur for the express benefit of conferring partial immunity eg [[sickle cell trait]], [[G6PD]], [[hereditary spherocytosis]]. At the same time, the parasite has evolved multiple ways of avoiding the immune system, which is why developing a [[Vaccination|vaccine]] has proved so difficult. It is likely that our [[Immunity|immune system]] has also evolved in response to pressure from the organism eg HLA B53 confers 40% protection vs severe malaria. |
| | <noinclude> | | <noinclude> |
| | {{SubjectBox}} | | {{SubjectBox}} |
-
Vaccine failure
New page: {{stub}} Category:Vaccination Vaccines are not 100% effective; and even if a vaccine were 100% effective in ideal circumstances, in the real world the vaccine programme may fail. The v...
New page {{stub}}
[[Category:Vaccination]]
Vaccines are not 100% effective; and even if a vaccine were 100% effective in ideal circumstances, in the real world the vaccine programme may fail. The vaccine may not be received, or may have spoiled in transit, for example.
==Heininger et al classifications of vaccine failure==
Ulrich Heininger and colleagues have categorised vaccine failures as follows:<ref>[http://www.ncbi.nlm.nih.gov/sites/entrez?itool=abstractplus&db=pubmed&cmd=Retrieve&dopt=abstractplus&list_uids=22197579 Heininger U, Bachtiar NS, Bahri P, Dana A, Dodoo A, Gidudu J, Santos EM. The concept of vaccination failure. Vaccine. 2011 Dec 21.]<small>(Epub ahead of print) </small><small>([http://dx.doi.org/10.1016/j.vaccine.2011.12.048 Link to article] – subscription may be required.)</small></ref>
===Vaccine failure===
====Vaccinee-related (host-related)====
#Immunodeficiency (leading to suboptimal or even absent immune response after vaccination)
#Insufficient or suboptimal immune response (other than a defined immunodeficiency) to one or more antigenic vaccine components or vaccine strains or serotypes (e.g. non-responders or low-responders to hepatitis B vaccine).
#Age-related maturation and senescence of immune responsiveness
#Waning immunity
#Suboptimal health status (e.g. underlying disease, nutrition)
#Interference due to other infectious agents (e.g. wild type enterovirus infection causing interference with the immune response to oral poliomyelitis vaccine, OPV)
#Immunological interference (e.g. maternal antibodies, administration of immunoglobulins)
#Pre-existing infection with pathogen targeted by the vaccine (e.g. with specific HPV genotypes) or immunization during incubation period (after exposure to pathogen)
====Vaccine-related====
#Vaccine is not 100% efficacious against included antigens
#Incomplete coverage of strains, serotypes, genotypes, antigenic variants, or escape mutants that can cause a vaccine preventable disease
#Antigenic interference or other vaccine?vaccine interactions in case of co-administered vaccines
#Manufacturing-related (e.g. batch variations, quality defect)
===Failure to vaccinate===
====Usage issues====
#Administration error (wrong or suboptimal route, inadequate dose, wrong diluent)
#Vaccination series incomplete, non-compliance with recommended schedule, including lack of recommended booster vaccination(s) (?failure to vaccinate? rather than ?vaccine failure?)
#Storage-related (e.g. cold chain)
#Vaccine beyond expiry date when used
====Immunization programme-related issues====
#Suboptimal recommendations regarding number and time points of primary and/or booster vaccinations
#Shortage of vaccine leading to no or incomplete vaccination (see also ''Vaccination series incomplete'' above).
{{Refsec}}
-
Herd immunity
| ?Older revision |
Revision as of 14:55, 6 February 2012 |
| Line 2: |
Line 2: |
| | {{BiteBox|Epidemics move like nuclear explosions, endemic disease like a moderated reactor, and if sufficient of the population are immune, the spread damps out.}} | | {{BiteBox|Epidemics move like nuclear explosions, endemic disease like a moderated reactor, and if sufficient of the population are immune, the spread damps out.}} |
| | | | |
| - | The multiplication factor (technically known as ''R'', the [[Reproductive number|''"reproductive number"'')]] is important in a chain reaction - if each infected case infects two more, a runaway propagation ensues. 1.1 and it burns. 0.5 and it fizzles out. We aim to move through the possibly quite small range of conditions between the critical population and the sub-critical by isolation, sanitation and immunisation. | + | The multiplication factor (technically known as ''R'', the [[Reproductive number|''"reproductive number"'')]] is important in a chain reaction - if each infected case infects two more, a runaway propagation ensues. 1.1 and it burns. 0.5 and it fizzles out. We aim to move through the possibly quite small range of conditions between the critical population and the sub-critical by isolation, sanitation and immunisation.<ref>[http://www.vaccinesinpractice.co.uk English PM. Herd immunity and reproduction numbers. Vaccines in Practice 2009;2(2):7-9.]</ref> |
| | | | |
| | Immunisation for purposes of herd immunity presents an ethical problem. Not a large or difficult one, and one where the consensus answer is often in favour of doing it, but one that needs thought and which varies according to what immunisation is being considered and for what disease. As is common in problems in the real world, no available immunisation is purely for herd or social benefit, and probably none is purely for personal benefit. This complicates the calculation, beyond the powers of many who attempt it and instead adopt a simpler absolutism but also unfortunately beyond the powers of many who should be explaining it and working from an understanding rather than by rote. | | Immunisation for purposes of herd immunity presents an ethical problem. Not a large or difficult one, and one where the consensus answer is often in favour of doing it, but one that needs thought and which varies according to what immunisation is being considered and for what disease. As is common in problems in the real world, no available immunisation is purely for herd or social benefit, and probably none is purely for personal benefit. This complicates the calculation, beyond the powers of many who attempt it and instead adopt a simpler absolutism but also unfortunately beyond the powers of many who should be explaining it and working from an understanding rather than by rote. |
| Line 13: |
Line 13: |
| | *[http://www.pitt.edu/~super1/lecture/lec1181/index.htm Supercourse "Herd Immunity and Vaccination" online lecture] | | *[http://www.pitt.edu/~super1/lecture/lec1181/index.htm Supercourse "Herd Immunity and Vaccination" online lecture] |
| | *[http://www.idready.org/slides/01epiconceptsII-notes.pdf Lecture ''"Concepts for the prevention and control of microbial threats ? 2".'' Center for Infectious Disease Preparedness, UC Berkeley School of Public Health.] | | *[http://www.idready.org/slides/01epiconceptsII-notes.pdf Lecture ''"Concepts for the prevention and control of microbial threats ? 2".'' Center for Infectious Disease Preparedness, UC Berkeley School of Public Health.] |
| | + | {{Refsec}} |
|
|
|
|
Site Visitors by Country
| Totals Top 5 |  | 49 % | Pakistan |  | 9 % | United States |  | 4 % | India |  | 3 % | United Kingdom |  | 2 % | China |
|